Score Your Stock

US stock · figures in US dollars · scored on full-year results

Insulet Insulet Corporation

PODD · Healthcare · Medical Devices
Top 10% of scored stocks
OkayTop 10% of scored stocks
Weak Spot

Insulet scores 71/100 on fundamentals: in the top 10% of 503 scored S&P 500 stocks. Its strongest area is Risk (100/100); its weakest is Price Fairness (17/100). It carries 1 warning flag: Weak Spot.

Best
Risk 100
Weakest
Price 17
  • Carries a Weak Spot flag

A financially strong, expensively priced stock with healthy growth, but price fairness needs attention.

What looks good
What to watch
Mkt capUS$ 10.4b#492 of 503 in the S&P 500EPSUS$ 5.34P/E27.7×✓ vs sector median 30.5×P/B7.3×✗ vs sector median 3.7×Div yieldNo dividends paidBottom 4% in the S&P 50052w range · 10% of range126.40354.88
as of 31 Oct 2026

Nearby peers

Ranks #5 of 60 in Healthcare by score

#1Universal Health Services79#3Steris75#4Dexcom73
#5Insulet71
#6Boston Scientific68#7Cooper Companies66

One-Minute Summary

Why Insulet scores 71

A financially strong, expensively priced stock with healthy growth, but price fairness needs attention.

What looks good
What to watch

Business Strength

90
Why 90?
Pillar score: (2 + 2 + 2 + 1 + 2) = 9 of 10 points → 90
Return on Equity (ROE)26%Strong4-Year Revenue Growth+22%/yrStrong4-Year Profit Growth+22%/yrStrongNet Profit Margin12%OkayQuarterly Momentum+29%Strong
Show 3 charts

Net Profit & Equity, with ROE

Net Profit ↑ +81.9%Equity ↑ +94.1%ROE % 26.4%
Net ProfitEquityROE %
206m418m247m375m733m1.2b1.5b1.4b202320242025TTM28.2%34.5%16.3%26.4%

Revenue & Net Profit, with Net Margin

Revenue ↑ +79.9%Net Profit ↑ +81.9%Net Margin % 12.3%
RevenueNet ProfitNet Margin %
1.7b2.1b2.7b3.1b206m418m247m375m202320242025TTM12.2%20.2%9.1%12.3%

Sales grew about 79.9% over 4 years: customers keep spending more with this company.

Profit climbed about 81.9% over 4 years: the business keeps more money as it grows.

Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)

Revenue ↑ +47.4%Net Profit ↑ +22.6%Net Margin % 11.8%
RevenueNet ProfitNet Margin %
544m598m569m649m706m784m762m802m78m101m35m23m88m102m91m95mQ3'24Q4'24Q1'25Q2'25Q3'25Q4'25Q1'26Q2'2614.2%16.9%6.2%3.5%12.4%13%12%11.8%
▲▬▼▼▲▬▲▲

Sales grew about 47.4% over the last 8 quarters: customers keep spending more with this company.

Profit grew about 22.6% over the last 8 quarters: the business is keeping more of what it earns.

Why 83?
Pillar score: (1 + 2 + 2) = 5 of 6 points → 83
Debt-to-Equity0.7×OkayCurrent Ratio2.5×StrongInterest Coverage9.4×Strong
Show 2 charts

Debt vs Equity, with D/E ratio

Total Debt ↓ -33%Equity ↑ +94.1%D/E 0.7×
Total DebtEquityD/E
1.4b1.4b949m948m733m1.2b1.5b1.4b202320242025TTM1.9×1.1×0.6×0.7×

Borrowings fell about 33% over 4 years: the company is steadily getting safer.

Short-term assets vs bills, with Current Ratio

Current Assets ↑ +16.8%Current Liabilities ↑ +64.9%Current Ratio 2.5×
Current AssetsCurrent LiabilitiesCurrent Ratio
1.6b1.9b1.9b1.8b451m528m680m744m202320242025TTM3.5×3.6×2.8×2.5×
Why 63?
Pillar score: (0 + 2 + 2 + 1) = 5 of 8 points → 63
Dividend QualityNo dividends paidWeak
Payout ratio: 0%
Operating Cash FlowPositive & growingStrongFree Cash FlowPositive & growingStrongCash & Cash EquivalentsPartly healthyOkay
Show 3 charts

Operating vs Free Cash Flow

Operating CF ↑ +250.9%Free CF ↑ +627.7%
Operating CFFree CF
146m430m569m511m37m296m350m266m202320242025TTM

The business generates real cash, and more of it each year: a very healthy sign.

Cash vs Total Debt

Cash ↓ -24%Short-Term Debt ↓ -61.7%Total Debt ↓ -33%
CashShort-Term DebtTotal Debt
704m953m716m535m49m84m18m19m1.4b1.4b949m948m202320242025TTM

Dividends per Share, with Yield

DPS (cents) → +0%Yield % 0%
DPS (cents)Yield %
000020222023202420250%0%0%0%

Dividends per share have been maintained or raised: management shares the rewards with you.

Why 17?
Pillar score: (0 + 0 + 1) = 1 of 6 points → 17
P/E Ratio27.7×WeakP/B Ratio7.3×WeakPEG Ratio1.3Okay
Show chart

Share Price: Weekly Closes (not part of the score)

US$ 332.70US$ 232.19US$ 131.69Oct '25Feb '26Jun '26Oct '26

The share price is down about 52.2% over the past year.

Why 100?
Pillar score: (2 + 2 + 2 + 2 + 2 + 2) = 12 of 12 points → 100
Earnings ConsistencySteadyStrongDebt Trend (4yr)FallingStrongShare Count Trend (4yr)-0%/yrStrongInventory vs Sales (4yr)-15.2 pp/yr vs salesStrongAsset Turnover Trend (4yr)+47.1%StrongQuarterly Consistency0 of 4 quarters downStrong
Show chart

Revenue vs Inventory, with Inventory % of Revenue

Revenue ↑ +79.9%Inventory ↑ +20.4%Inv. % of Rev. 15.9%
RevenueInventoryInv. % of Rev.
1.7b2.1b2.7b3.1b403m430m453m485m202320242025TTM23.7%20.8%16.7%15.9%
Ranks #5 of 60 in Healthcare by score

Sector peers

#1Universal Health Services79#3Steris75#4Dexcom73
#5Insulet (you)71
#6Boston Scientific68#7Cooper Companies66

Full Financial History

Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.

Financial YearRevenueNet ProfitOperating Cash FlowFree Cash FlowCapExCashTotal DebtShort-Term DebtEquityCurrent AssetsCurrent LiabilitiesTotal AssetsTotal LiabilitiesInventoryDividendsReturn on Equity (ROE)Net Profit MarginDebt-to-EquityCurrent RatioInterest CoverageDiv yieldP/E RatioP/B RatioPEG Ratio
2026US$ 3.1bUS$ 375.3mUS$ 511.2mUS$ 265.6mUS$ -245.6mUS$ 534.9mUS$ 948.4mUS$ 18.9mUS$ 1.4bUS$ 1.8bUS$ 744.2mUS$ 3.2bUS$ 1.7bUS$ 484.8m-26%12%0.7×2.5×9.4×----
2025US$ 2.7bUS$ 247.1mUS$ 569.3mUS$ 349.9mUS$ -219.4mUS$ 716.1mUS$ 949.2mUS$ 18.4mUS$ 1.5bUS$ 1.9bUS$ 680.1mUS$ 3.2bUS$ 1.7bUS$ 452.6mUS$ 0.0m16%9%0.6×2.8×6.7×0%80.6×13.1×0.3
2024US$ 2.1bUS$ 418.3mUS$ 430.2mUS$ 296.2mUS$ -134.0mUS$ 953.3mUS$ 1.4bUS$ 83.8mUS$ 1.2bUS$ 1.9bUS$ 528.4mUS$ 3.1bUS$ 1.9bUS$ 430.4mUS$ 0.0m35%20%1.1×3.6×8.0×0%44.7×15.4×0.1
2023US$ 1.7bUS$ 206.3mUS$ 145.7mUS$ 36.5mUS$ -109.2mUS$ 704.2mUS$ 1.4bUS$ 49.4mUS$ 732.7mUS$ 1.6bUS$ 451.2mUS$ 2.6bUS$ 1.9bUS$ 402.6mUS$ 0.0m28%12%1.9×3.5×6.9×0%73.5×20.7×0.0